𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Fontolizumab (Huzaf), a humanized anti-IFN-gamma antibody, has clinical activity and excellent tolerability in moderate to severe Crohn’s disease

✍ Scribed by Daniel Hommes; Tatiana Mikhajlova; Simeon Stoinov; Davor Stimac; Boris Vucelic; Janos Lonovics; Maria Zakuciova; Geert D’Haens; Gert Van Assche; Tillman Pearce

Book ID
119757861
Publisher
Elsevier Science
Year
2004
Tongue
English
Weight
45 KB
Volume
127
Category
Article
ISSN
0016-5085

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I, double-blind, randomized, place
Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease
✍ C. Janneke van der Woude; Pieter Stokkers; Ad A. van Bodegraven; Gert Van Assche 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 274 KB 👁 2 views

Background: NI-0401 is a fully human monoclonal antibody, which binds to the CD3 subunit of the T-cell receptor, causing modulation of T-cell activity. We investigated the safety and the ability to modulate the TCR-CD3 complex of NI-0401 in patients with active Crohn's disease (CD). Methods: A doub